Robert Korngold
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Robert Korngold has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Fred D. Lublin
1 shared publicationGabor Varadi
Kimmel Cancer Institute Jefferson Medical College Philadelphia Pennsylvania
1 shared publicationGeorge F Murphy
Department of Pathology, Jefferson Medical College, Philadelphia, Pennsylvania, USA
1 shared publicationGeorge F. Murphy
1 shared publication- Jeymohan Joseph
Department of Neurology, Jefferson Medical College, Philadelphia, Pennsylvania
1 shared publication Jill Giles-Komar
Research and Development, Centocor, Inc, Malvern, Pennsylvania, USA
1 shared publication
Latest Publications
- Open Access
- 15 December 2003
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 112 (12) , 1880-1886
Importance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell–mediated graft-versus-host disease model
Minor histocompatibility antigens with expression restricted to the recipient hematopoietic compartment represent prospective immunological targets for graft-versus-leukemia therapy. It remains unclear, however, whether donor T cell recognition of these hematopoietically derived minor histocompatibility antigens will induce significant graft-versus-host disease (GVHD). Using established bone marrow irradiation chimeras across the multiple minor histocompatibility antigen–disparate, C57BL/6→BALB.B combination, we studied the occurrence of lethal GVHD mediated by CD4+ T cells in recipient mice expressing only hematopoietically derived alloantigens. Even substantial dosages of donor C57BL/6 CD4+ T cells were unable to elicit lethal GVHD when transplanted into [BALB.B→C57BL/6] chimeras. Instead, chimeric mice displayed transient cachexia with reduced target-tissue injury over time, reflecting an early, limited, graft-versus-host response. On the other hand, the importance of minor histocompatibility antigens derived from nonhematopoietic tissues was demonstrated by the finding that [C57BL/6→BALB.B] chimeric mice succumbed to C57BL/6 CD4+ T cell–mediated GVHD. These data suggest that severe acute CD4+ T cell–mediated GVHD across this minor histocompatibility antigen barrier depends on the expression of nonhematopoietically rather than hematopoietically derived alloantigens for maximal target-tissue infiltration and injury.
- 15 December 2003
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 112 (12) , 1880-1886
Open AccessImportance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell–mediated graft-versus-host disease model
Minor histocompatibility antigens with expression restricted to the recipient hematopoietic compartment represent prospective immunological targets for graft-versus-leukemia therapy. It remains unclear, however, whether donor T cell recognition of these hematopoietically derived minor histocompatibility antigens will induce significant graft-versus-host disease (GVHD). Using established bone marrow irradiation chimeras across the multiple minor histocompatibility antigen–disparate, C57BL/6→BALB.B combination, we studied the occurrence of lethal GVHD mediated by CD4+ T cells in recipient mice expressing only hematopoietically derived alloantigens. Even substantial dosages of donor C57BL/6 CD4+ T cells were unable to elicit lethal GVHD when transplanted into [BALB.B→C57BL/6] chimeras. Instead, chimeric mice displayed transient cachexia with reduced target-tissue injury over time, reflecting an early, limited, graft-versus-host response. On the other hand, the importance of minor histocompatibility antigens derived from nonhematopoietic tissues was demonstrated by the finding that [C57BL/6→BALB.B] chimeric mice succumbed to C57BL/6 CD4+ T cell–mediated GVHD. These data suggest that severe acute CD4+ T cell–mediated GVHD across this minor histocompatibility antigen barrier depends on the expression of nonhematopoietically rather than hematopoietically derived alloantigens for maximal target-tissue infiltration and injury.
- Open Access
- 1 May 2003
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 9 (5) , 292-303
Role of tumor necrosis factor-α in graft-versus-host disease and graft-versus-leukemia responses
- 1 May 2003
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 9 (5) , 292-303
Open AccessRole of tumor necrosis factor-α in graft-versus-host disease and graft-versus-leukemia responses
- Open Access
- 1 June 2002
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 8 (6) , 303-315
Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk
- 1 June 2002
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 8 (6) , 303-315
Open AccessLeucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk
- 1 January 1991
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 1991, 3
Survival and immunogenicity of neural grafts
- 1 January 1991
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 1991, 3
Survival and immunogenicity of neural grafts